Author:
Garrido-Castro A. C.,Metzger-Filho O.
Publisher
Springer Science and Business Media LLC
Reference84 articles.
1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). doi: 10.1093/jnci/dju055 .
2. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer (version 2.2016). National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Accessed August 5, 2016.
3. Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32(29):3307–29. doi: 10.1200/JCO.2014.56.7479 .
4. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003;9(1 Pt 2):447S–54.
5. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573–83. doi: 10.1038/nrclinonc.2015.117 .
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献